SLC5A2 and diabetes mellitus: Questions remain about the mechanism of action of SGLT2 inhibitors and GLP-RAs, particularly in relation to the cardiorenal benefits observed in some diabetes CVOTs [110–112] (Additional file 2: Fig. S2).